Mandvi Bharadwaj
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mandvi Bharadwaj has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
D.J Moss
Co-operative Research Centre for Vaccine Technology, Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane, Australia 4029
1 shared publicationDenis J Moss
CCRC.I, Queensland Institute of Medical Research, Royal Brisbane Hospital Post Office, Brisbane 4029, Queensland, Australia
1 shared publicationDenis J. Moss
Queensland Institute of Medical Research, Brisbane, Australia
1 shared publicationM Sherritt
Co-operative Research Centre for Vaccine Technology, Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane, Australia 4029
1 shared publication- Peter G. Parsons
QIMR Berghofer Medical Research Institute PO Royal Brisbane Hospital Brisbane 4029 QLD Australia
1 shared publication - Rajiv Khanna
QIMR Berghofer Medical Research Institute
1 shared publication
Latest Publications
- 1 December 2002
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 1 (4) , 467-476
Epstein-Barr virus vaccine: a cytotoxic T-cell-based approach
EpsteinBarr virus infects more than 95% of the human population and is linked to infectious mononucleosis as well as a series of geographicallydefined cancers. To date, there is no prophylactic or therapeutic vaccine available for Epstein-Barr virus-associated diseases. New immunotherapeutic approaches, based on cytotoxic T-cells, are being developed depending on the degree of Epstein-Barr virus antigen expression in infected cells. It is hoped that these approaches will provide enough impetus for cytotoxic T-cell-based vaccine development. Approaches for developing vaccines towards the different Epstein-Barr virus-associated diseases are discussed.
- 1 December 2002
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 1 (4) , 467-476
Epstein-Barr virus vaccine: a cytotoxic T-cell-based approach
EpsteinBarr virus infects more than 95% of the human population and is linked to infectious mononucleosis as well as a series of geographicallydefined cancers. To date, there is no prophylactic or therapeutic vaccine available for Epstein-Barr virus-associated diseases. New immunotherapeutic approaches, based on cytotoxic T-cells, are being developed depending on the degree of Epstein-Barr virus antigen expression in infected cells. It is hoped that these approaches will provide enough impetus for cytotoxic T-cell-based vaccine development. Approaches for developing vaccines towards the different Epstein-Barr virus-associated diseases are discussed.
- Open Access
- 1 January 2001
- Published by Taylor & Francis in BioTechniques
- Vol. 30 (1) , 36-38
Cost-Efficient Quantification of Enzyme-Linked Immunospot
- 1 January 2001
- Published by Taylor & Francis in BioTechniques
- Vol. 30 (1) , 36-38
Open AccessCost-Efficient Quantification of Enzyme-Linked Immunospot